Treatment with brigatinib, or Alunbrig, showed substantial response in patients with non-small cell lung cancer and intracranial involvement, according to a study published in the Journal of Clinical Oncology. Researchers feel that brigatinib holds promise as a potential first-line treatment to delay or prevent brain metastases.
Brigatinib may prevent brain metastases in NSCLC, study shows
Sign up for SNMMI SmartBrief
Nuclear medicine and molecular imaging news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.